182 results
424B3
QLGN
Qualigen Therapeutics Inc
3 May 24
Prospectus supplement
1:50pm
prospectus that we have authorized. We take no responsibility for, and can provide no assurance as to the reliability of, any other information
POS AM
QLGN
Qualigen Therapeutics Inc
30 Apr 24
Prospectus update (post-effective amendment)
6:58pm
no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The shares are not being
8-K
EX-10.4
QLGN
Qualigen Therapeutics Inc
16 Apr 24
Entry into a Material Definitive Agreement
4:10pm
manufacturer will remain the Company and, at an appropriate time and if necessary, the Company will develop and enter into a quality assurance agreement … , at the reasonable request of the Company and at the Company’s sole cost, an order or other assurance that confidential treatment will be accorded
8-K
EX-10.1
mnj7ygxyzn3rvhbbe
27 Feb 24
Entry into a Material Definitive Agreement
7:00am
8-K
jrytw8vv1 oum
22 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
EX-99.1
9ac 61r5rortyvkgi
14 Nov 23
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
5:10pm
8-K
EX-99.1
367h nptdam8
8 Nov 23
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
2:16pm
424B3
f3f2bvppy2 gjcv
29 Sep 23
Prospectus supplement
4:30pm
POS AM
uztzvw8dc9xcgz92
1 Sep 23
Prospectus update (post-effective amendment)
4:15pm
8-K
EX-99.1
9vg7i6z4jsg 0wzi
15 Aug 23
Results of Operations and Financial Condition
10:04am